Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoSTAR: Neoadjuvant Sacituzumab Govitecan in Localized TNBC
NCT04230109Phase 2Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Jul 2020
- Primary completion
- Oct 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab govitecan in triple-negative breast cancer (TNBC), sponsored by Massachusetts General Hospital. Started Jul 2020; status: recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04230109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04230109.